These effects are compounded by the apoptosis of BBB microvascular endothelial cells caused by hyperglycemia and obesity
Note: At maximum doses (Trulicity 4.5mg), A1C reduction increases to 1.8%, making efficacy more comparable
\Improved Blood Flow: May promote the growth of new blood vessels and enhance circulation in injured areas
Without insurance, Wegovy costs approximately $1,300-$1,500 monthly, Saxenda $1,300-$1,400 monthly, and Zepbound $1,000-$1,200 monthly
These particles can be further functionalized with ligands (e.g., peptides or antibodies) that target receptors highly expressed on specific lung cells involved in COPD pathogenesis, such as CD44 on alveolar macrophages